

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 June 2005 (16.06.2005)

PCT

(10) International Publication Number
WO 2005/054249 A1

(51) International Patent Classification⁷: **C07D 491/10**,
221/20, 209/54, A61K 31/438, 31/403, 31/407, A61P
11/06, 11/08, 19/02, 29/00

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,
S-151 85 Södertälje (SE).

(21) International Application Number:
PCT/SE2004/001771

(22) International Filing Date:
30 November 2004 (30.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0303280-2 5 December 2003 (05.12.2003) SE

(71) Applicant (for all designated States except US): **AS-
TRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HOSSAIN, Nafizal**
[SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE).
IVANOVA, Svetlana [RU/SE]; AstraZeneca R & D Lund,
S-221 87 Lund (SE). **MENSONIDES-HARSEMA, Mar-
guerite** [NL/SE]; AstraZeneca R & D Lund, S-221 87 Lund
(SE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS



(57) Abstract: The invention provides compounds of formula (I) wherein m , R^1 , n , R^2 , q , X , Y , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

WO 2005/054249 A1

NOVEL COMPOUNDS

The present invention relates to novel compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

5


Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved
10 four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.

15 The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and
20 MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β).

Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2,
25 CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

In accordance with the present invention, there is therefore provided a compound of formula



wherein

5 m is 0, 1, 2, 3 or 4;

each R^1 independently represents halogen, cyano, hydroxyl, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylsulphonyl or sulphonamido ($-SO_2NH_2$);

X represents a bond or $-CH_2-$ and Y represents a bond or $-CH_2-$, provided that X and Y do not both simultaneously represent a bond or $-CH_2-$;

10 n is 0, 1 or 2;

each R^2 independently represents halogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl ;

q is 0 or 1;

R^3 represents a saturated or unsaturated 5- to 10-membered ring system other than phenyl, which ring system may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one
 15 substituent selected from halogen, cyano, oxo, nitro, hydroxyl, carboxyl, $-C(O)H$, $-NR^9R^{10}$, $-C(O)NR^{11}R^{12}$, $-NHC(O)R^{13}$, $-NHSO_2R^{14}$, $-SO_2NR^{15}R^{16}$, $-NHC(O)NR^{17}R^{18}$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, C_1 - C_6 alkylsulphonyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy C_1 - C_6 alkyl, C_1 - C_6 alkylcarbonyl, phenylcarbonyl,
 20 C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkylmethyl and a saturated or unsaturated 5- to 6-membered heterocyclic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur;

R^4 , R^5 , R^6 , R^7 and R^8 each independently represent hydrogen, halogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl ;

25 R^9 and R^{10} each independently represent hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl;

R^{11} and R^{12} each independently represent hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, or R^{11} and R^{12} together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring which may be optionally substituted with at least one substituent selected from hydroxyl;

5 R^{13} and R^{14} each independently represent C₁-C₆ alkyl, C₃-C₆ cycloalkyl or C₁-C₄ haloalkyl;

R^{15} and R^{16} each independently represent hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, or R^{15} and R^{16} together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring which may be optionally substituted with at least one substituent selected from hydroxyl; and

10 R^{17} and R^{18} each independently represent hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, or R^{17} and R^{18} together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring which may be optionally substituted with at least one substituent selected from hydroxyl;

15 or a pharmaceutically acceptable salt or solvate thereof.

In the context of the present specification, unless otherwise stated, an alkyl substituent group or alkyl moiety in a substituent group may be linear or branched. A haloalkyl substituent group will comprise at least one halogen atom, e.g. one, two, three, four or five
20 halogen atoms. In the ring substituted by R^2 , R^2 may be attached to any suitable ring carbon atom including the carbon atom of (CH₂)_q. An unsaturated ring or ring system will be partially or fully unsaturated. Further, when R^{11} and R^{12} or R^{15} and R^{16} or R^{17} and R^{18} represent a 4- to 7-membered saturated heterocyclic ring, it should be understood that the only heteroatom present is the nitrogen atom to which R^{11} and R^{12} or R^{15} and R^{16} or
25 R^{17} and R^{18} are attached.

In an embodiment of the invention, m is 0 or 1, particularly 1.

Each R^1 independently represents halogen (e.g. chlorine, fluorine, bromine or iodine),
30 cyano, hydroxyl, C₁-C₆, preferably C₁-C₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl,

n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), C₁-C₆, preferably C₁-C₄, haloalkyl (e.g. trifluoromethyl or pentafluoroethyl), C₁-C₆, preferably C₁-C₄, alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxo or n-hexoxo), C₁-C₆, preferably C₁-C₄, alkylsulphonyl (e.g. methylsulphonyl, ethylsulphonyl, n-propylsulphonyl, isopropylsulphonyl, n-butylsulphonyl, isobutylsulphonyl, tert-butylsulphonyl, n-pentylsulphonyl or n-hexylsulphonyl) or sulphonamido.

In an embodiment of the invention, each R¹ independently represents halogen, C₁-C₆, preferably C₁-C₄, alkyl or C₁-C₆, preferably C₁-C₄, haloalkyl.

In another embodiment, each R¹ independently represents fluorine, chlorine, methyl or trifluoromethyl, particularly chlorine.

In an embodiment of the invention, X represents a bond and Y represents -CH₂-.

Each R² independently represents halogen (e.g. chlorine, fluorine, bromine or iodine), C₁-C₆, preferably C₁-C₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or C₁-C₆, preferably C₁-C₄, haloalkyl (e.g. trifluoromethyl or pentafluoroethyl).

In an embodiment of the invention, n is 0 or n is 1 and R² represents halogen, particularly fluorine.

R³ represents a saturated or, preferably, unsaturated 5- or 6- to 7-, 8-, 9- or 10-membered ring system other than phenyl, which ring system may comprise at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent (e.g. one, two, three or four substituents independently) selected from halogen (e.g. chlorine, fluorine, bromine or iodine), cyano, oxo (=O), nitro, hydroxyl, carboxyl, -C(O)H, -NR⁹R¹⁰, -C(O)NR¹¹R¹², -NHC(O)R¹³, -NHSO₂R¹⁴, -SO₂NR¹⁵R¹⁶,

- NHC(O)NR¹⁷R¹⁸, C₁-C₆, preferably C₁-C₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl),
 C₁-C₆, preferably C₁-C₄, alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexoxy),
 5 C₁-C₆, preferably C₁-C₄, alkylthio (e.g. methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, tert-butylthio, n-pentylthio or n-hexylthio),
 C₁-C₆, preferably C₁-C₄, alkylsulphonyl (e.g. methylsulphonyl, ethylsulphonyl, n-propylsulphonyl, isopropylsulphonyl, n-butylsulphonyl, isobutylsulphonyl, tert-butylsulphonyl, n-pentylsulphonyl or n-hexylsulphonyl),
 10 C₁-C₆, preferably C₁-C₄, haloalkyl (e.g. trifluoromethyl or pentafluoroethyl),
 C₁-C₆ alkoxyC₁-C₆ alkyl (e.g. C₁-C₄ alkoxyC₁-C₆ alkyl or C₁-C₂ alkoxyC₁-C₆ alkyl or C₁-C₄ alkoxyC₁-C₄ alkyl or C₁-C₂ alkoxyC₁-C₂ alkyl such as methoxymethyl),
 C₁-C₆, preferably C₁-C₄, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, isobutylcarbonyl,
 15 tert-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), phenylcarbonyl,
 C₃-C₆ cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl),
 C₃-C₆ cycloalkylmethyl (cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl or cyclohexylmethyl), and
 a saturated or unsaturated 5- to 6-membered heterocyclic ring comprising at least one ring
 20 heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from
 nitrogen, oxygen and sulphur (e.g. one or more of pyrrolidinyl, piperidinyl, piperazinyl, dithiolanyl, morpholinyl, tetrahydropyranyl, thiomorpholinyl, pyrazolyl, pyrazinyl, pyridazinyl, thiazolidinyl, thienyl, isoxazolyl, pyrimidinyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl and pyridinyl, preferably thienyl,
 25 dithiolanyl and pyridinyl).

The saturated or unsaturated 5- to 10-membered ring system in R³ may be carbocyclic or heterocyclic. Examples of suitable ring systems, which may be monocyclic or polycyclic (e.g. bicyclic) where the two or more rings are fused, include one or more (in any
 30 combination) of cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, cyclopentenyl,

cyclohexenyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, diazabicyclo[2.2.1]hept-2-yl, naphthyl, benzofuranyl, benzothienyl, benzodioxolyl, isoquinolinyl, quinolinyl, 1,2-dihydroquinolinyl, 1,2,3,4-tetrahydroquinolinyl, 2,3-dihydrobenzoxazinyl, quinazolinyl, 1,2,3,4-tetrahydroquinazolinyl, 2,3-dihydrobenzofuranyl, pyrazolyl, pyrazinyl, thiazolidinyl, indanyl, thienyl, isoxazolyl, pyridazinyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, benzothiazolyl, indolyl, imidazolyl, pyrimidinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl.

Preferred ring systems include quinolinyl, 1,2-dihydroquinolinyl, 1,2,3,4-tetrahydroquinolinyl, 2,3-dihydrobenzoxazinyl, 1,2,3,4-tetrahydroquinazolinyl, naphthyl, pyridinyl, benzofuranyl, benzothiazolyl, pyrimidinyl, isoquinolinyl and quinazolinyl.

In an embodiment of the invention, R^3 represents an unsaturated 6- to 10-membered ring system, which ring system may comprise one, two or three ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent (e.g. one, two, three or four substituents independently selected from halogen, cyano, oxo, nitro, hydroxyl, carboxyl, $-C(O)H$, $-NR^9R^{10}$, $-C(O)NR^{11}R^{12}$, $-NHC(O)R^{13}$, $-NHSO_2R^{14}$, $-SO_2NR^{15}R^{16}$, $-NHC(O)NR^{17}R^{18}$, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, C_1 - C_4 alkylsulphonyl, C_1 - C_4 haloalkyl, C_1 - C_4 alkoxy C_1 - C_4 alkyl, C_1 - C_4 alkylcarbonyl, phenylcarbonyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkylmethyl and a saturated or unsaturated 5- to 6-membered heterocyclic ring comprising one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur.

In another embodiment of the invention, R^3 represents an unsaturated 6- to 10-membered ring system, which ring system may comprise one or two ring heteroatoms independently selected from nitrogen and oxygen (e.g. quinolinyl, 1,2-dihydroquinolinyl, 1,2,3,4-tetrahydroquinolinyl, 2,3-dihydrobenzoxazinyl, 1,2,3,4-tetrahydroquinazolinyl, naphthyl, pyridinyl, benzofuranyl, pyrimidinyl, isoquinolinyl and quinazolinyl), or two ring heteroatoms consisting of nitrogen and sulphur (e.g. benzothiazolyl), the ring system being

optionally substituted with one, two or three substituents independently selected from halogen, oxo, nitro, -NH_2 , $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_1\text{-C}_4$ alkoxy, $\text{C}_1\text{-C}_4$ alkylthio, $\text{C}_1\text{-C}_4$ haloalkyl, $\text{C}_1\text{-C}_4$ alkoxy $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_1\text{-C}_4$ alkylcarbonyl, $\text{C}_3\text{-C}_6$ cycloalkylmethyl, $\text{-C(O)NR}^{11}\text{R}^{12}$, carboxyl and a saturated or unsaturated 5- to 6-
5 membered heterocyclic ring comprising one or two ring heteroatoms independently selected from nitrogen and sulphur (e.g. thienyl, dithiolanyl and pyridinyl).

In a further embodiment of the invention, R^3 represents an unsaturated 6- to 10-membered ring system selected from quinolinyl, 1,2-dihydroquinolinyl, 1,2,3,4-tetrahydroquinolinyl, 10 2,3-dihydrobenzoxazinyl, 1,2,3,4-tetrahydroquinazolinyl, naphthyl, pyridinyl, benzofuranyl, benzothiazolyl, pyrimidinyl, isoquinolinyl and quinazolinyl, the ring system being optionally substituted with one, two or three substituents independently selected from chlorine, bromine, iodine, oxo, nitro, -NH_2 , $\text{C}_1\text{-C}_4$ alkyl, methoxy, methylthio, trifluoromethyl, methoxymethyl, methylcarbonyl, cyclopropylmethyl, 15 carboxyl, thienyl, dithiolanyl, pyridinyl, and $\text{C(O)NR}^{11}\text{R}^{12}$ where R^{11} represents hydrogen and R^{12} represents methyl or R^{11} and R^{12} together with the nitrogen form a pyrrolidinyl group substituted by hydroxyl.

R^4 , R^5 , R^6 , R^7 and R^8 each independently represent hydrogen, halogen (e.g. chlorine, 20 fluorine, bromine or iodine), $\text{C}_1\text{-C}_6$, preferably $\text{C}_1\text{-C}_4$, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or $\text{C}_1\text{-C}_6$, preferably $\text{C}_1\text{-C}_4$, haloalkyl (e.g. trifluoromethyl or pentafluoroethyl).

In an embodiment of the invention, R^4 , R^5 , R^6 , R^7 and R^8 each independently represent a 25 hydrogen atom or a methyl group.

In another embodiment of the invention, R^4 , R^5 , R^6 and R^7 each represent a hydrogen atom and R^8 represents a methyl group.

30 In an embodiment of the invention, R^4 , R^5 , R^6 , R^7 and R^8 each represent a hydrogen atom.

R^9 and R^{10} each independently represent hydrogen, C_1 - C_6 , preferably C_1 - C_4 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or C_3 - C_6 , preferably C_3 or C_5 - C_6 , cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or
5 cyclohexyl).

In an embodiment of the invention, R^9 and R^{10} each represent hydrogen.

R^{11} and R^{12} each independently represent hydrogen, C_1 - C_6 , preferably C_1 - C_4 , alkyl (e.g.
10 methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or C_3 - C_6 , preferably C_3 or C_5 - C_6 , cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), or R^{11} and R^{12} together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring (e.g. pyrrolidinyl or piperidinyl) which may be optionally substituted with at least one substituent (e.g. one, two or three
15 substituents independently) selected from hydroxyl.

In an embodiment of the invention, R^{11} and R^{12} each independently represent hydrogen, C_1 - C_4 alkyl or C_3 or C_5 - C_6 cycloalkyl, or R^{11} and R^{12} together with the nitrogen atom to which they are attached form a 5- to 6-membered saturated heterocyclic ring which may
20 be optionally substituted with one or two hydroxyl groups.

In another embodiment, R^{11} and R^{12} each independently represent hydrogen, C_1 - C_2 alkyl or C_3 or C_5 - C_6 cycloalkyl, or R^{11} and R^{12} together with the nitrogen atom to which they are attached form a 5-membered saturated heterocyclic ring which may be optionally
25 substituted with one hydroxyl group.

R^{13} and R^{14} each independently represent C_1 - C_6 , preferably C_1 - C_4 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl, particularly methyl), C_3 - C_6 , preferably C_3 or C_5 - C_6 , cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl

or cyclohexyl) or C₁-C₄, preferably C₁-C₂, haloalkyl (e.g. trifluoromethyl or pentafluoroethyl).

R¹⁵ and R¹⁶ each independently represent hydrogen, C₁-C₆, preferably C₁-C₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or C₃-C₆, preferably C₃ or C₅-C₆, cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), or R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring (e.g. pyrrolidinyl or piperidinyl) which may be optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from hydroxyl.

R¹⁷ and R¹⁸ each independently represent hydrogen, C₁-C₆, preferably C₁-C₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or C₃-C₆, preferably C₃ or C₅-C₆, cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), or R¹⁷ and R¹⁸ together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring (e.g. pyrrolidinyl or piperidinyl) which may be optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from hydroxyl.

In an embodiment of the invention:

m is 1;

R¹ represents halogen (particularly chlorine);

X represents a bond;

Y represents -CH₂-;

n is 0;

q is 1;

R³ represents an unsaturated 6- to 10-membered ring system selected from quinolinyl, 1,2-dihydroquinolinyl, 1,2,3,4-tetrahydroquinolinyl, 2,3-dihydrobenzoxazinyl, 1,2,3,4-tetrahydroquinazolinyl, naphthyl, pyridinyl, benzofuranyl, pyrimidinyl, isoquinolinyl, benzothiazolyl and quinazolinyl, the ring system being optionally

substituted with one, two or three substituents independently selected from chlorine, bromine, iodine, oxo, nitro, C₁-C₄ alkyl, methoxy, methylthio, trifluoromethyl, methoxymethyl, methylcarbonyl, cyclopropylmethyl, thienyl, dithiolanyl, -NH₂, carboxyl, pyridinyl, and C(O)NR¹¹R¹² where R¹¹ represents hydrogen and R¹² represents methyl or R¹¹ and R¹² together with the nitrogen form a pyrrolidinyl group substituted by hydroxyl ; and
R⁴, R⁵, R⁶, R⁷ and R⁸ each independently represent hydrogen.

Examples of compounds of the invention include:

- 10 8-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-3,4-dihydroquinolin-2(1*H*)-one,
8-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}quinolin-2(1*H*)-one,
5-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-2*H*-1,4-benzoxazin-3(4*H*)-one,
15 8-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}quinazoline-2,4(1*H*,3*H*)-dione trifluoroacetate (salt),
(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(1-naphthyloxy)propan-2-ol trifluoroacetate (salt),
20 (2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(6-methyl-2-nitropyridin-3-yl)oxy]propan-2-ol trifluoroacetate (salt),
1-(6-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4,7-dimethoxy-1-benzofuran-5-yl)ethanone trifluoroacetate (salt),
(2*S*)-1-[(6-Chloropyridin-2-yl)oxy]-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol trifluoroacetate (salt),
25 (2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[[7-(trifluoromethyl)quinolin-4-yl]oxy]propan-2-ol trifluoroacetate (salt),
(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-iodo-6-methylpyridin-3-yl)oxy]propan-2-ol trifluoroacetate (salt),

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{[5-(cyclopropylmethyl)-6-methyl-2-pyridin-4-ylpyrimidin-4-yl]oxy}propan-2-ol trifluoroacetate (salt),

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(quinolin-8-yloxy)propan-2-ol trifluoroacetate (salt),

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(isoquinolin-5-yloxy)propan-2-ol trifluoroacetate (salt),

(2*S*)-1-[(6-Bromoquinazolin-4-yl)oxy]-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol trifluoroacetate (salt),

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{[2-(2-thienyl)-6-(trifluoromethyl)pyrimidin-4-yl]oxy}propan-2-ol trifluoroacetate (salt),

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(quinolin-5-yloxy)propan-2-ol trifluoroacetate (salt),

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2,3,4-trichloro-1-naphthyl)oxy]propan-2-ol trifluoroacetate (salt),

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{[1-(1,3-dithiolan-2-yl)-2-naphthyl]oxy}propan-2-ol trifluoroacetate (salt),

(2*S*)-1-{[5-Butyl-6-(methoxymethyl)-2-(methylthio)pyrimidin-4-yl]oxy}-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol trifluoroacetate (salt),

(2*S*)-1-[(2-Amino-1,3-benzothiazol-4-yl)oxy]-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-methyl-1,3-benzothiazol-4-yl)oxy]propan-2-ol,

(2*S*)-1-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-methyl-1-benzofuran-4-yl)oxy]propan-2-ol,


3-{[(2*S*)-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}isonicotinic acid,

3-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-*N*-methylisonicotinamide,


(3*S*)-1-(3-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}isonicotinoyl)pyrrolidin-3-ol,
and pharmaceutically acceptable salts and solvates of any one thereof.

- 5 The present invention further provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined above which comprises,

(a) reacting a compound of formula




- 10 wherein m , R^1 , n , R^2 , q , X and Y are as defined in formula (I), with a compound of formula




wherein R^3 , R^4 , R^5 , R^6 , R^7 and R^8 are as defined in formula (I); or

(b) reacting a compound of formula




- 15 wherein m , R^1 , n , R^2 , q , X , Y , R^4 , R^5 , R^6 , R^7 and R^8 are as defined in formula (I), with a compound of formula




wherein R^3 is as defined in formula (I), in the presence of a suitable base (for example, triethylamine or potassium carbonate);

(c) when R^3 is substituted with $-C(O)NR^{11}R^{12}$, reacting a compound of formula



wherein L represents a leaving group (e.g. a hydroxyl group), $R^{3'}$ is a saturated or unsaturated 5- to 10-membered ring system other than phenyl, which ring system may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, [and which ring system may be further substituted with a substituent other than $-C(O)NR^{11}R^{12}$ as defined for R^3 in formula (I)] and m , R^1 , n , R^2 , q , X , Y , Z , R^4 , R^5 , R^6 , and R^7 are as defined in formula (I), with a compound of formula (VII),



wherein R^{11} and R^{12} are as defined in formula (I), in the presence of a suitable coupling reagent (e.g. ethyl chloridocarbonate or 1,1'-carbonylbis-1*H*-imidazole); and optionally after (a), (b) or (c) forming a pharmaceutically acceptable salt or solvate.

The processes of the invention may conveniently be carried out in a solvent, e.g. an organic solvent such as an alcohol (e.g. methanol or ethanol), a hydrocarbon (e.g. toluene) or tetrahydrofuran, dimethylformamide, N-methylpyrrolidinone, dichloromethane or acetonitrile at a temperature of, for example, 0°C or above such as a temperature in the range from 0, 5, 10, 15 or 20°C to 100, 110 or 120°C .

Compounds of formulae (II), (III), (IV), (V) and (VII) are either commercially available, are known in the literature or may be prepared using known techniques.

- 5 Compound (VI) can be prepared according to the general processes described in process (a) and process (b).

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the reagents may
10 need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups.

The protection and deprotection of functional groups is described in 'Protective Groups in
15 Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 3rd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1999).

The compounds of formula (I) above may be converted to a pharmaceutically acceptable
20 salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

Compounds of formula (I) are capable of existing in stereoisomeric forms. It will be
25 understood that the invention encompasses the use of all geometric and optical isomers (including atropisomers) of the compounds of formula (I) and mixtures thereof including racemates. The use of tautomers and mixtures thereof also form an aspect of the present invention. Enantiomerically pure forms are particularly desired.

The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially MIP-1 α chemokine receptor) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative and hyperproliferative diseases and immunologically-mediated diseases including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS).

Examples of these conditions are:

- (1) **(the respiratory tract)** airways diseases including chronic obstructive pulmonary disease (COPD) such as irreversible COPD; asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
- (2) **(bone and joints)** rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;
- (3) **(skin)** psoriasis, atopic dermatitis, contact dermatitis and other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis;
- (4) **(gastrointestinal tract)** Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;

- (5) **(other tissues and systemic disease)** multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, sezary syndrome and idiopathic thrombocytopenia pupura;
- (6) **(allograft rejection)** acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;
- (7) cancers, especially non-small cell lung cancer (NSCLC) and squamous sarcoma;
- (8) diseases in which angiogenesis is associated with raised chemokine levels; and
- (9) cystic fibrosis, stroke, re-perfusion injury in the heart, brain, peripheral limbs and sepsis.

Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

The invention also provides a method of treating an inflammatory disease (e.g. rheumatoid arthritis) which comprises administering to a patient in need thereof a therapeutically

effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

5 The invention still further provides a method of treating an airways disease (e.g. asthma or chronic obstructive pulmonary disease) which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

10 For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound of formula (I) may be in the range from 0.001 mg/kg to 30 mg/kg.

15 The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, 20 still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore 25 defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a 30 pharmaceutically acceptable adjuvant, diluent or carrier.

The pharmaceutical compositions may be administered topically (e.g. to the skin or to the lung and/or airways) in the form, e.g., of creams, solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules; or by parenteral administration in the form of solutions or suspensions; or by subcutaneous administration; or by rectal administration in the form of suppositories; or transdermally.

The invention will now be further explained by reference to the following illustrative examples, in which ^1H NMR spectra were recorded on Varian Unity Inova 400. The central solvent peak of chloroform- d (δ_{H} 7.27 ppm), acetone- d_6 (δ_{H} 2.05 ppm), DMSO- d_6 (δ_{H} 2.50 ppm), or methanol- d_4 (δ_{H} 4.87 ppm) were used as internal standard. Low resolution mass spectra and accurate mass determination were recorded on a Hewlett-Packard 1100 LC-MS system equipped with APCI /ESI ionisation chambers.

All solvents and commercial reagents were laboratory grade and used as received. The nomenclature used for the compounds was generated with ACD/Name and ACD/Name Batch. The abbreviations or terms used in the examples have the following meanings:

DMF : *N,N*-dimethylformamide

MeOH : methanol

DCM : dichloromethane

THF : tetrahydrofuran


DME : 1,2-dimethoxyethane

NMP : *N*-methylpyrrolidinone

Examples

Intermediate Compound: 5-Chloro-3*H*-spiro[1-benzofuran-2,4'-piperidine]

Method A: This compound was prepared as described by Effland, R. C; Gardner, B. A; Strupczewski, J., *J. Heterocyclic Chem.*, **1981**, 18, 811-814.

Method B:**i) 1-Oxa-6-azaspiro[2.5]octane-6-carboxylic acid, 1,1-dimethylethyl ester**

Potassium t-butoxide (31g) was added to a stirred suspension of trimethylsulfoxonium iodide (60.8g) in 1,2-dimethoxyethane (250ml) at 20°C. After 1 hour, the mixture was added portionwise over 30 minutes to a stirred solution of 4-oxo-1-piperidinecarboxylic acid, 1,1-dimethylethyl ester (50g) in 1,2-dimethoxyethane (50ml) at 0°C. After a further 2 hours, water (500ml) was added and the mixture extracted with *tert.*-butyl methyl ether (2 × 500ml). The organic extracts were washed separately with saturated sodium bicarbonate solution (250ml), combined, dried over anhydrous magnesium sulphate, filtered and evaporated under reduced pressure. The residual oil was co-evaporated with toluene (100ml) to give the sub-title compound (43.25g, 81 %) as a solid.

¹H-NMR (400 MHz, CDCl₃): δ 1.46 (9H, s), 1.43-1.48 (2H, m), 1.75-1.84 (2H, m), 2.69 (2H, s), 3.38-3.47 (2H, m), 3.70-3.75 (2H, m).

(ii) 5-Chlorospiro[1-benzofuran-2,4'-piperidine]-1'-carboxylic acid, 1,1-dimethyl ester

A solution of iso-propylmagnesium chloride in tetrahydrofuran (2M, 106.6ml) was added dropwise over 15 minutes to a stirred solution of 2-bromo-4-chloro-1-fluorobenzene (42.5g) in anhydrous tetrahydrofuran (250ml) at 0°C under nitrogen. After a further 15 minutes, a solution of 1-oxa-6-azaspiro[2.5]octane-6-carboxylic acid, 1,1-dimethylethyl ester (43.2g) in anhydrous tetrahydrofuran (50ml) was added followed by

copper(I)bromide dimethyl sulphide complex (0.4g). The mixture was stirred at 40°C for 18 hours, cooled to 20°C, diluted with water (300ml) and extracted with with *tert.*-butyl methyl ether (2 × 300ml). Organic extracts were dried over anhydrous magnesium sulphate, filtered and evaporated under reduced pressure. The residual oil was dissolved in
5 1,2-dimethoxypropane (200ml). Potassium *tert.*-butoxide (22.8g) was added and the mixture stirred at 40°C for 16 hours then at 50°C for 24 hours. Further potassium *tert.*-butoxide (5.7g) was added and stirring continued at 50°C for 2 hours then at 55°C for 4 hours. Water (500ml) was added and the mixture extracted with *tert.*-butyl methyl ether (2 × 300ml). Organic extracts were dried over anhydrous magnesium sulphate, filtered and
10 evaporated under reduced pressure to give the sub-title compound (47.45g, 67 %) as an oil.

¹H-NMR (400 MHz, CDCl₃): δ 1.47 (9H, s), 1.67 (2H, td), 1.85-1.93 (2H, m), 2.94 (2H, s), 3.39 (2H, td), 3.65-3.80 (2H, m), 6.67 (1H, d), 7.06 (1H, d), 7.10 (1H, s).

15 **iii) 5-Chlorospiro[1-benzofuran-2,4'-piperidine]**

Concentrated hydrochloric acid (23ml) was added to a solution of 5-chlorospiro[1-benzofuran-2,4'-piperidine]-1'-carboxylic acid, 1,1-dimethyl ester (46.43g) in tetrahydrofuran (230ml). The mixture was stirred at 50°C for 6 hours, cooled to 20°C, diluted with water (230ml) and extracted with *tert.*-butyl methyl ether (2 × 230ml). The
20 aqueous phase was adjusted to pH >10 by addition of 50wt.% sodium hydroxide solution and extracted with *tert.*-butyl methyl ether (3 × 300ml). Organic extracts were dried over anhydrous magnesium sulphate, filtered and evaporated under reduced pressure. The residual oil was dissolved in tetrahydrofuran (240ml), concentrated hydrochloric acid (12ml) was added and the mixture stirred at 20°C for 16 hours. Precipitated solid was
25 filtered and dissolved in water (100ml). The solution was adjusted to pH >10 by addition of 50wt.% sodium hydroxide solution and extracted with *tert.*-butyl methyl ether (3 × 100ml) to give the title compound (13.3g, 45 %) as a solid.

¹H-NMR (400 MHz, CDCl₃): δ 1.69-1.76 (2H, m), 1.83-1.87 (2H, m), 2.78-2.84 (2H, m),
30 2.98-3.03 (4H, m), 6.65 (1H, d), 7.04 (1H, d), 7.13 (1H, s).

APCI-MS: m/z 224/6 [M+H]⁺

Example 1

8- $\{[(2S)$ -3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy $\}$ -3,4-dihydroquinolin-2(1*H*)-one

Step I:

3-Chloro-*N*-(2-hydroxyphenyl)propanamide

To a stirred solution of 2-aminophenol (2.18 g, 20 mmol) in acetone (20 ml) was added dropwise a solution of 3-chloropropanoyl chloride (1.28 g, 10 mmol) in acetone (20 ml). The mixture was stirred for 30 min, then water (50 ml) was added. Acetone was removed in vacuo. The precipitate was collected by filtration and dried to afford subtitle compound (1.53 g, 77 %).

¹H-NMR (400 MHz, DMSO-*d*₆): δ 9.75 (s, 1H), 9.37 (s, 1H), 7.77 (d, *J* = 7.8 Hz, 1H), 6.91 (m, 2H), 6.76 (t, *J* = 7.5 Hz, 1H), 3.86 (t, *J* = 6.2 Hz, 2H), 2.91 (t, *J* = 6.2 Hz, 2H).

APCI-MS: m/z 200 (MH⁺).

Step II:

8-Hydroxy-3,4-dihydroquinolin-2(1*H*)-one

A mixture of 3-chloro-*N*-(2-hydroxyphenyl)propanamide (0.25 g, 1.25 mmol) and AlCl₃ (0.5 g) was heated with stirring at 130 °C for 5 h. After cooling to room temperature, the reaction mixture was quenched with water (3 ml). The resulting suspension was extracted with ethyl acetate (3 x 5 ml). Evaporation of solvent from combined extracts and purification by flash chromatography on silica gel (ethyl acetate/heptane) afforded colourless crystals (95 mg, 47 %).

¹H-NMR (400 MHz, DMSO-*d*₆): δ 9.64 (s, 1H), 8.76 (s, 1H), 6.75 (m, 1H), 6.65 (m, 2H), 2.83 (t, *J* = 7.4 Hz, 2H), 2.43 (t, *J* = 7.5 Hz, 2H).

APCI-MS: m/z 164 (MH⁺).

Step III:**5-Chloro-1'-[(2*S*)-oxiran-2-ylmethyl]-3*H*-spiro[1-benzofuran-2,4'-piperidine]**

A solution of 5-chloro-3*H*-spiro[1-benzofuran-2,4'-piperidine] (0.22 g, 1 mmol) and (2*R*)-
5 2-(chloromethyl)oxirane (92 mg, 1 mmol) in dry ethanol (5 ml) was stirred at room
temperature for 36 hours. A solution of sodium methoxide in methanol (0.5 M, 2 ml) was
added dropwise, and the stirring was continued at room temperature for 1 hour. The
inorganic precipitate was removed by filtration. The solvent was removed in vacuo, and
the residue purified by flash chromatography on silica gel (dichloromethane/methanol,
10 1 : 1) to afford a colourless oil (0.20 g, 71 %).

¹H-NMR (400 MHz, CDCl₃): δ 7.09 (s, 1H), 7.05 (ddd, *J* = 0.2, 8.2, 2.0 Hz, 2H), 6.66
(d, *J* = 8.5 Hz, 1H), 3.13 (sextet, *J* = 3.4 Hz, 1H), 2.97 (s, 2H), 2.79 (m, 2H), 2.75 - 2.57
(m, 4H), 2.51 (dd, *J* = 5.0, 2.7 Hz, 1H), 2.36 (dd, *J* = 13.4, 6.7 Hz, 1H), 1.99 (m, 2H),
15 1.84 (m, 2H).
APCI-MS: *m/z* 280 (MH⁺).

Step IV:**8-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-
20 hydroxypropyl]oxy}-3,4-dihydroquinolin-2(1*H*)-one**

A mixture of 8-hydroxy-3,4-dihydroquinolin-2(1*H*)-one (25 mg, 0.16 mmol), 5-chloro-1'-
[(2*S*)-oxiran-2-ylmethyl]-3*H*-spiro[1-benzofuran-2,4'-piperidine] (40 mg, 0.14 mmol), and
K₂CO₃ (30 mg, 0.22 mmol) in DMF (1 ml) was stirred at 110 °C for 24 hours. After
cooling to room temperature, the inorganic material was removed by filtration. The filtrate
25 was concentrated in vacuo. Purification by semi-preparative HPLC yielded the title
compound (16 mg, 25 %).

¹H-NMR (400 MHz, DMSO-*d*₆): δ 9.50 (s, 1H), 7.23 (s, 1H), 7.09 (dd, *J* = 8.4, 2.1 Hz,
1H), 6.91 - 6.71 (m, 4H), 5.30 (d, *J* = 5.2 Hz, 1H), 4.01 (d, *J* = 7.2 Hz, 2H), 3.80 (dd, *J* =

9.8, 7.4 Hz, 1H), 2.99 (s, 2H), 2.87 (t, $J = 7.5$ Hz, 2H), 2.65 (m, 1H), 2.60 - 2.41 (m, 6H), 1.86 - 1.68 (m, 4H)

APCI-MS: m/z 443 (MH^+).

5 **Example 2**

8-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}quinolin-2(1*H*)-one

Step I:

10 **8-Hydroxyquinolin-2(1*H*)-one**

Quinolin-8-ol 1-oxide (20 g, 124 mmol) in acetic anhydride (200 ml) was stirred at 90 °C for 5 hours. Then the reaction mixture was poured into water/ice mixture (1.5 L), and made neutral by addition of conc. aq. NH_3 . The precipitate formed was collected by filtration and washed with water. The crude product was purified by suspending in propan-2-ol and
15 addition of petroleum ether to give 2-oxo-1,2-dihydroquinolin-8-yl acetate. 2-Oxo-1,2-dihydroquinolin-8-yl acetate was heated in conc. aq. HCl (200 ml) at 90 °C for 4 hours. The reaction mixture was poured into ice-cold water (400 ml), and the precipitate formed was collected by filtration and washed with water. Recrystallization from propan-2-ol / petroleum ether afforded the subtitle compound (14.1 g, 70 %).

20

1H -NMR (400 MHz, $DMSO-d_6$): δ 10.46 (s, 1H), 10.21 (s, 1H), 7.84 (d, $J = 9.5$ Hz, 1H), 7.10 (d, $J = 7.6$ Hz, 1H), 7.00 (t, $J = 7.7$ Hz, 1H), 6.95 (dd, $J = 7.8, 1.2$ Hz, 1H), 6.48 (d, $J = 9.5$ Hz, 1H)

APCI-MS: m/z 162 (MH^+).

25

Step II:

8-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}quinolin-2(1*H*)-one

The title compound was prepared from 8-hydroxyquinolin-2(1*H*)-one (28 mg, 0.1 mmol) using the procedure described in Example 1, Step IV. Purification by preparative HPLC afforded 44 mg (38 %).

- 5 ¹H-NMR (400 MHz, DMSO-*d*₆): δ 11.17 (s, 1H), 7.90 (d, *J* = 9.5 Hz, 1H), 7.25 (m, 2H), 7.10 (m, 3H), 6.74 (d, *J* = 8.5 Hz, 1H), 6.53 (d, *J* = 9.6 Hz, 1H), 5.45 (d, *J* = 5.5 Hz, 1H), 4.14 (dd, *J* = 9.2, 2.5 Hz, 1H), 4.09 (t, *J* = 5.9 Hz, 1H), 3.92 (dd, *J* = 9.0, 6.8 Hz, 1H), 3.00 (s, 2H), 2.67 (br.s, 1H), 2.60 - 2.41 (m, 5H, partially covered with the signal of solvent), 1.86 - 1.69 (m, 4H)
- 10 APCI-MS: *m/z* 441 (MH⁺).

Example 3

5-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-2*H*-1,4-benzoxazin-3(4*H*)-one

15

Step I:

2-Aminobenzene-1,3-diol

- A mixture of 2-nitrobenzene-1,3-diol (5 g, 32.2 mmol) and 10% Pd on charcoal (230 mg) in ethanol (100 ml) were hydrogenated with H₂ at atmospheric pressure overnight. The
- 20 reaction mixture was filtered through celite. Ethanol was removed by evaporation to yield the subtitled compound (4 g, 99%).

¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.81 (br.s, 2H), 6.24 (m, 3H), 3.81 (br.s, 2H).
APCI-MS: *m/z* 126.0 (MH⁺).

25

Step II:

2-Chloro-*N*-(2,6-dihydroxyphenyl)acetamide

- KH₂PO₄ (17.2 g, 126.3 mmol) and K₂HPO₄ (8.2 g, 35.7 mmol) in 188 ml of distilled water were deoxygenated by passing argon through the mixture for 0.5 hour. 2-Aminobenzene-
- 30 1,3-diol (1 g, 8.0 mmol) was added to the buffer solution and chloroacetyl chloride (0.64

ml, 8.0 mmol) was added slowly to the reaction mixture. After addition was completed, the reaction mixture was stirred at room temperature for 1.5 hours. Water was removed by freeze-drying and the residue was dissolved in 20% MeOH in DCM. The insoluble salt was removed by filtration, the solvent was evaporated to give the subtitled compound
5 which was used without purification in the next step.

APCI-MS: m/z 202.0 (MH^+).

Step III:

10 **5-Hydroxy-2*H*-1,4-benzoxazin-3(4*H*)-one**

2-Chloro-*N*-(2,6-dihydroxyphenyl)acetamide (1.99 g, 9.88 mmol) was dissolved in 150 ml of 10% aqueous K_2CO_3 and the solution was heated to 40°C for 45 minutes. After cooling and neutralization with 2M HCl the reaction mixture was extracted with ethyl acetate. Drying with $MgSO_4$ and evaporation of solvent afforded crude material (0.54 g, overall
15 yield from Steps II and III 41 %).

APCI-MS: m/z 166.0 (MH^+).

Step IV:

20 **5-[[[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-2*H*-1,4-benzoxazin-3(4*H*)-one**

A mixture of 5-hydroxy-2*H*-1,4-benzoxazin-3(4*H*)-one (64.7 mg, 0.38 mmol), 5-chloro-1'-[(2*S*)-oxiran-2-ylmethyl]-3*H*-spiro[1-benzofuran-2,4'-piperidine] (105.3 mg, 0.38 mmol), K_2CO_3 (108.7 mg, 0.75 mmol) and DMF (4 ml) was heated at 110°C overnight. After
25 cooling the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with water and then evaporated. The residue was purified by preparative HPLC (eluant: [acetonitrile /water]) to afford the titled compound (8 mg, 4.6 %).

1H -NMR (400 MHz, $DMSO-d_6$): δ 10.23 (s, 1H), 7.25 (s, 1H), 7.09 (dd, $J = 8.5, 2.2$ Hz, 1H), 6.87 (t, $J = 8.3$ Hz, 1H), 6.74 (d, $J = 8.5$ Hz, 1H), 6.66 (d, $J = 12.8$ Hz, 1H), 6.58 (d, J
30

= 8.1 Hz, 1H), 5.20 (br.s, 1H), 4.55 (s, 2H), 4.02 (m, 2H), 3.83 (m, 1H), 3.00 (s, 2H), 2.72-2.41 (br.m, 6H, partially covered with the signal of solvent), 1.79 (m, 4H).

APCI-MS: m/z 445.2 (MH^+).

5 **Example 4**

8-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}quinazoline-2,4(1*H*,3*H*)-dione trifluoroacetate (salt)

Step I:

10 **8-Hydroxyquinazoline-2,4(1*H*,3*H*)-dione**

2-Amino-3-hydroxybenzoic acid (195 mg, 1.28 mmol), urea (243 mg, 4.0 mmol) and NMP (10 ml) were heated in microwave oven (200°C, 250 W) for 20 minutes. The reaction mixture was purified by preparative HPLC (eluant: [acetonitrile /water/ trifluoroacetic acid]) to afford the subtitled compound (65 mg, 29%)

15 .

1H -NMR (400 MHz, DMSO- d_6): δ 11.19 (s, 1H), 10.35 (s, 1H), 10.22 (s, 1H), 7.35 (dd, J = 7.8, 0.8 Hz, 1H), 7.07 (dd, J = 7.8, 1.3 Hz, 1H), 6.99 (t, J = 7.8 Hz, 1H).

APCI-MS: m/z 178.9 (MH^+).

20 **Step II:**

8-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}quinazoline-2,4(1*H*,3*H*)-dione trifluoroacetate (salt)

The title compound was prepared from 8-hydroxyquinazoline-2,4(1*H*,3*H*)-dione (65.1 mg, 0.37 mmol) using the procedure described in Example 3, Step IV. Purification by
25 preparative HPLC (eluant: [acetonitrile /water/trifluoroacetic acid]) afforded the titled compound (6 mg, 2.9 %).

1H -NMR (400 MHz, DMSO- d_6): δ 11.40 (s, 1H), 10.42 (s, 1H), 9.52 (br.s, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.30 (s, 1H), 7.29 (d, J = 7.0 Hz, 1H), 7.17 (d, J = 8.6 Hz, 1H), 7.15 (t, J =
30 8.0 Hz, 1H), 6.80 (d, J = 8.6 Hz, 1H), 6.17 (d, J = 4.1 Hz, 1H), 4.43 (br.s, 1H), 4.11 (m,

1H), 3.96 (m, 1H), 3.64-3.17 (br.m, 6H, partially covered with the signal of solvent), 3.12 (s, 2H), 2.22-2.03 (m, 4H).

APCI-MS: m/z 458.2 (MH⁺).

5 **Example 5**

(2S)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(1-naphthyloxy)propan-2-ol trifluoroacetate (salt)

A slurry of 1-naphthol (100 µL, 0.5 M in dimethylformamide), (2S)-oxiran-2-ylmethyl 3-nitrobenzenesulfonate (100 µL, 0.5 M in dimethylformamide) and cesium carbonate (13 mg, 0.04 mmol) was stirred at room temperature overnight, and then partitioned between water and dichloromethane. The organic phase was evaporated, and the resulting crude (2S)-2-[(1-naphthyloxy)methyl]oxirane was dissolved in ethanol (400 µL) and 5-chloro-3*H*-spiro[1-benzofuran-2,4'-piperidine] (100 µL, 0.5 M in dimethylformamide) was added.
15 The mixture was refluxed overnight, and the solvent was evaporated. Purification was performed on by semi-preparative HPLC, with acetonitrile/water 0.1% trifluoroacetic acid as mobile phase. Pure fractions were collected, pooled and evaporated to give the title compound.

20 APCI-MS m/z: 424 [MH⁺]

The following Examples 6 to 19 were prepared by methods analogous to the method described in Example 5.

25 **Example 6**

(2S)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(6-methyl-2-nitropyridin-3-yl)oxy]propan-2-ol trifluoroacetate (salt)

APCI-MS m/z: 434 [MH⁺]

Example 7

1-(6-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4,7-dimethoxy-1-benzofuran-5-yl)ethanone trifluoroacetate (salt)

5 APCI-MS m/z: 516 [MH⁺]

Example 8

(2*S*)-1-[(6-Chloropyridin-2-yl)oxy]-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol trifluoroacetate (salt)

10

APCI-MS m/z: 409 [MH⁺]

Example 9

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{[7-(trifluoromethyl)quinolin-4-yl]oxy}propan-2-ol trifluoroacetate (salt)

15

APCI-MS m/z: 493 [MH⁺]

Example 10

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-iodo-6-methylpyridin-3-yl)oxy]propan-2-ol trifluoroacetate (salt)

20

APCI-MS m/z: 515 [MH⁺]

Example 11

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{[5-(cyclopropylmethyl)-6-methyl-2-pyridin-4-ylpyrimidin-4-yl]oxy}propan-2-ol trifluoroacetate (salt)

25

30 APCI-MS m/z: 521 [MH⁺]

Example 12

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(quinolin-8-yloxy)propan-2-ol trifluoroacetate (salt)

5

APCI-MS m/z: 425 [MH⁺]

Example 13

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(isoquinolin-5-yloxy)propan-2-ol trifluoroacetate (salt)

10

APCI-MS m/z: 425 [MH⁺]

Example 14

(2*S*)-1-[(6-Bromoquinazolin-4-yl)oxy]-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol trifluoroacetate (salt)

15

APCI-MS m/z: 505 [MH⁺]

Example 15

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{[2-(2-thienyl)-6-(trifluoromethyl)pyrimidin-4-yl]oxy}propan-2-ol trifluoroacetate (salt)

20

APCI-MS m/z: 526 [MH⁺]

25

Example 16

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(quinolin-5-yloxy)propan-2-ol trifluoroacetate (salt)

30 APCI-MS m/z: 425 [MH⁺]

Example 17

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2,3,4-trichloro-1-naphthyl)oxy]propan-2-ol trifluoroacetate (salt)

5

APCI-MS m/z: 526 [MH⁺]

Example 18

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{[1-(1,3-dithiolan-2-yl)-2-naphthyl]oxy}propan-2-ol trifluoroacetate (salt)

10

APCI-MS m/z: 528 [MH⁺]

Example 19

(2*S*)-1-{{[5-Butyl-6-(methoxymethyl)-2-(methylthio)pyrimidin-4-yl]oxy}-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol trifluoroacetate (salt)

15

APCI-MS m/z: 524 [MH⁺]

Example 20

(2*S*)-1-[(2-Amino-1,3-benzothiazol-4-yl)oxy]-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol

20

Step I:**2-Amino-1,3-benzothiazol-4-ol**

25

To a cold solution (ice-water bath) of 4-methoxy-1,3-benzothiazol-2-amine (360 mg, 2 mmol) in CH₂Cl₂ (10 mL) was slowly added a solution of BBr₃ in CH₂Cl₂ (1 M, 5 mL, 5 mmol). After the addition was completed, the ice-bath was removed and the reaction mixture was stirred at room temperature for 24 h, cooled to 0 °C, and quenched with methanol (3 mL). After stirring for 30 min the volatiles were removed i.vac.. The residue

30

was dissolved in ethyl acetate (100 mL), washed successively with aqueous NaHCO₃ (3 x 10 mL) and H₂O (10 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated to give crude sub title compound (270 mg).

5 ¹H-NMR (400 MHz, DMSO-*d*₆): δ 9.20 (s, 1H); 7.20 (s, 2H); 7.05 (dd, *J* = 0.8, 7.7 Hz, 1H); 6.82 (t, *J* = 7.8 Hz, 1H); 6.64 (dd, *J* = 0.8, 7.8 Hz, 1H).

Step II:

(2S)-1-[(2-Amino-1,3-benzothiazol-4-yl)oxy]-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol

A mixture of 2-amino-1,3-benzothiazol-4-ol (100 mg, 0.6 mmol), (2S)-oxiran-2-ylmethyl-3-nitrobenzenesulfonate (156 mg, 0.6 mmol) and Cs₂CO₃ (195 mg, 0.6 mmol) in DMF (3 mL) was stirred at room temperature over night. The mixture was partitioned between ethyl acetate and H₂O. The organic layer was dried over Na₂SO₄, and filtered. 5-Chloro-3*H*-spiro[1-benzofuran-2,4'-piperidine] (134 mg, 0.6 mmol) was added to the filtrate, and the solution was concentrated in vacuo. The residue was taken into ethanol (3 mL) and stirred at 75 °C for 3 h. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2 % methanol in CH₂Cl₂ containing 0.2% ammonia) to give title compound (60 mg).

20 ¹H-NMR (400 MHz, DMSO-*d*₆): δ 7.41 (s, 2H); 7.24 (m, 2H); 7.09 (dd, *J* = 2.3, 8.5 Hz, 1H); 6.94 (t, *J* = 7.9 Hz, 1H); 6.84 (d, *J* = 8.1 Hz, 1H); 6.74 (d, *J* = 8.5 Hz, 1H); 4.82 (s, 1H); 4.08 (m, 1H); 3.98 (m, 2H); 3.00 (s, 2H); 2.68-2.38 (m, 6H); 1.80 (m, 4H).
APCI-MS: *m/z* 446 [MH⁺].

Example 21

(2S)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-methyl-1,3-benzothiazol-4-yl)oxy]propan-2-ol

30 **Step I:**

***N*-(2-Methoxyphenyl)ethanethioamide**

A suspension of *N*-(2-methoxyphenyl)acetamide (2.4 g, 15 mmol) and P₂S₅ (6.66 g, 15 mmol) in ethyl acetate (60 mL) was refluxed for 2 h, cooled to room temperature and partitioned between aqueous NaHCO₃ and CH₂Cl₂. The layers were separated, the organic layer was washed with aqueous NaHCO₃ and H₂O successively, dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography (0-20% ethyl acetate in petroleum spirit 40-60) to give sub title compound (1.16 g).

¹H-NMR (400 MHz, CDCl₃): δ 9.70 (br.s, 1H); 9.00 (dd, *J* = 1.2, 8.1 Hz, 1H); 7.18 (m, 1H); 7.05 – 6.94 (m, 2H); 3.94 (s, 3H); 2.79 (s, 3H).
APCI-MS: *m/z* 182 [MH⁺].

Step II:**4-Methoxy-2-methyl-1,3-benzothiazole**

An solution of aqueous NaOH solution (4% wt, 25 mL) was added slowly to *N*-(2-methoxyphenyl)ethanethioamide, followed by a solution of potassium ferricyanide (4.36 g, 13.24 mmol) in water (19 mL). After the addition was completed, the reaction mixture was stirred at room temperature over night, and then extracted with diethyl ether (3x 30 mL). The combined organic layer was washed with water (3 x 10 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-0.8% methanol in dichloromethane containing 0.2% ammonia) to give sub title compound (315 mg).

¹H-NMR (400 MHz, DMSO-*d*₆): δ 7.41 (dd, *J* = 0.9, 8.1 Hz, 1H); 7.30 (t, *J* = 8.0 Hz, 1H); 6.89 (d, *J* = 8.0 Hz, 1H); 4.01 (s, 3H); 2.83 (s, 3H).
APCI-MS: *m/z* 180 [MH⁺].

Step III:**2-Methyl-1,3-benzothiazol-4-ol**

To a cold (ice-water bath) solution of 4-methoxy-2-methyl-1,3-benzothiazole (310 mg, 1.73 mmol) in dichloromethane (8 mL) was slowly added a solution of BBr_3 in dichloromethane (1 M, 4.32 mL, 4.32 mmol). After the addition was completed, the reaction mixture was stirred at room temperature for 24 h. Then the reaction mixture was cooled in ice-water bath, and quenched with methanol (2 mL). The ice bath was removed, the reaction mixture was stirred 20 min. The volatiles were removed in vacuo, and the residue was dissolved in ethyl acetate (200 mL), washed successively with aqueous NaHCO_3 and water. The organic layer was dried over Na_2SO_4 , filtered and concentrated. The residue was purified by silica gel flash chromatography (0-0.9 % methanol in dichloromethane containing 0.2% ammonia) to give sub title compound (140 mg).

$^1\text{H-NMR}$ (400 MHz, $\text{DMSO}-d_6$): δ 10.01 (br.s, 1H); 7.38 (d, $J = 7.8$ Hz, 1H); 7.18 (t, $J = 8.0$ Hz, 1H); 6.82 (d, $J = 7.8$ Hz, 1H); 2.81 (s, 3H).

Step IV:

2-Methyl-4-[(2S)-oxiran-2-ylmethoxy]1,3-benzothiazole

A mixture of 2-methyl-1,3-benzothiazol-4-ol (100 mg, 0.6 mmol), (2S)-oxiran-2-ylmethyl-3-nitrobenzenesulfonate (156 mg, 0.6 mmol) and Cs_2CO_3 (254 mg, 0.78 mmol) in DMF (5 mL) was stirred at room temperature over night. The mixture was partitioned between ethyl acetate and water. The organic layer was dried over Na_2SO_4 , filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography (0-40% ethyl acetate in petroleum spirit 40-60) to give sub title compound (95 mg).

$^1\text{H-NMR}$ (400 MHz, CDCl_3): δ 7.44 (d, $J = 8.0$ Hz, 1H); 7.28 (t, $J = 8.0$ Hz, 1H); 6.98 (d, $J = 8.0$ Hz, 1H); 4.45 (dd, $J = 3.7, 11.5$ Hz, 1H); 4.30 (dd, $J = 5.5, 11.5$ Hz, 1H); 3.56 (m, 1H); 2.95 (t, $J = 4.5$ Hz, 1H); 2.86 (s, 3H); 2.80 (dd, $J = 2.6, 4.9$ Hz, 1H).

Step V:

(2S)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-methyl-1,3-benzothiazol-4-yl)oxy]propan-2-ol

A mixture of 5-chloro-3*H*-spiro[1-benzofuran-2,4'-piperidine] (37 mg, 0.167 mmol) and 2-methyl-4-[(2*S*)-oxiran-2-ylmethoxy]1,3-benzothiazole (35 mg, 0.167 mmol) in ethanol (1.5 mL) was stirred at 78 °C for 4 h, cooled to room temperature, and the volatiles were removed in vacuo. The residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane containing 0.2% ammonia) to give title compound (42 mg).

¹H-NMR (400 MHz, CD₃OD): δ 7.49 (d, *J* = 8.0 Hz, 1H); 7.34 (t, *J* = 8.0 Hz, 1H); 7.14 (s, 1H); 7.04 (m, 2H); 6.66 (d, *J* = 8.5 Hz, 1H); 4.32 – 4.23 (m, 2H); 4.06 (dd, *J* = 6.5, 9.3 Hz, 1H); 3.01 (s, 2H); 2.84 (s, 3H); 2.79 – 2.64 (m, 6H); 1.99-1.81 (m, 4H).
APCI-MS: *m/z* 445 [MH⁺].

Example 22

(2*S*)-1-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-methyl-1-benzofuran-4-yl)oxy]propan-2-ol

15

Step I:

2-methyl-1-benzofuran-4-ol

Prepared as described (T. Reichstein, R. Hirt, *Helv. Chim. Acta* **1933**, *16*, 121 – 125).

¹H-NMR (400 MHz, CDCl₃): δ 7.09 – 7.03 (m, 2H), 6.61 (dd, *J* = 6.6, 2.0 Hz, 1H), 6.45 (s, 1H), 5.56 (br. s, 1H), 2.44 (s, 3H)

Step II:

2-methyl-4-[(2*S*)-oxiran-2-ylmethoxy]-1-benzofuran

A mixture of 2-methyl-1-benzofuran-4-ol (66 mg, 0.45 mmol), (2*S*)-oxiran-2-ylmethyl-3-nitrobenzenesulfonate (115 mg, 0.45 mmol) and Cs₂CO₃ (176 mg, 0.54 mmol) in DMF (3 mL) was stirred at room temperature over night. The mixture was partitioned between ethyl acetate and water. The organic layer was dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography (ethyl acetate/*n*-heptane, 1 : 1) to give subtitle compound (72 mg, 78 %).

¹H-NMR (400 MHz, CDCl₃): δ 7.15 – 7.07 (m, 2H), 6.63 (d, *J* = 7.4 Hz, 1H), 6.51 (s, 1H), 4.34 (dd, *J* = 11.1, 3.1 Hz, 1H), 4.08 (dd, *J* = 11.1, 5.6 Hz, 1H), 3.42 (m, 1H), 2.93 (t, *J* = 4.5 Hz, 1H), 2.79 (dd, *J* = 4.9, 2.6 Hz, 1H), 2.45 (s, 3H)

5

Step III:

(2*S*)-1-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-methyl-1-benzofuran-4-yl)oxy]propan-2-ol

A mixture of 5-chloro-3*H*-spiro[1-benzofuran-2,4'-piperidine] (37 mg, 0.17 mmol) and 2-methyl-4-[(2*S*)-oxiran-2-ylmethoxy]-1-benzofuran (34 mg, 0.17 mmol) in ethanol (2 mL) was stirred at 78 °C overnight, cooled to room temperature, and the volatiles were removed in vacuo. Purification was performed on by semi-preparative HPLC, with acetonitrile / water containing 0.1% trifluoroacetic acid as mobile phase to give the title compound (54 mg, 59 %).

15

¹H-NMR (400 MHz, CDCl₃): δ 7.18 – 7.07 (m, 4H), 6.69 (d, *J* = 8.5 Hz, 1H), 6.63 (d, *J* = 7.3 Hz, 1H), 6.47 (s, 1H), 4.60 (m, 1H), 4.27 (dd, *J* = 9.6, 4.3 Hz, 1H), 4.09 (dd, *J* = 9.4, 7.6 Hz, 1H), 3.74 (m, 2H), 3.44 – 3.25 (m, 4H), 3.10 (s, 2H), 2.46 (s, 3H), 2.41 (q, *J* = 17.1 Hz, 2H), 2.15 (t, *J* = 13.5 Hz, 2H)

APCI-MS: *m/z* 428 [MH⁺].

20

Example 23

3-[(2*S*)-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}isonicotinic acid

25

Step I:**Ethyl 3-hydroxyisonicotinate**

Method A: 3-Hydroxyisonicotinic acid (974 mg, 7.0 mmol) and 1,1'-carbonylbis-1*H*-imidazole (CDI) (1.3 g, 8 mmol) were stirred in THF (10 mL) at 70 °C 1h. The mixture was dissolved in a solution of sodium ethylate (0.5 g, 7 mmol) in ethanol (100 mL). After

30

evaporation *in vacuo* and extraction from DCM and 1M sodium hydrogen carbonate solution the subtitled compound was isolated from the washed organic phase as a yellow solid (803 mg, 69%).

Method B: To a slurry of 3-hydroxyisonicotinic acid (0.56 g, 4 mmol) in ethanol (25 mL) was added thionylchloride (2.35 mL, 32 mmol) at 0°C. The mixture was heated with reflux for 15 h. The solvent was evaporated *in vacuo* and the residue partitioned between DCM and 1M sodium hydrogencarbonate solution. The subtitle compound was isolated from the washed organic phase as a yellow solid (0.63 g, 94%)

¹H NMR (400 MHz, CDCl₃): δ 10.37 (br. s, 1H), 8.49 (s, 1H), 8.22 (d, *J* = 5.2 Hz, 1H), 7.64 (d, *J* = 5.2 Hz, 1H), 4.46 (q, *J* = 7.2 Hz, 2H), 1.44 (t, *J* = 7.2 Hz, 3H)
APCI-MS: *m/z* 168 [MH⁺]

Step II:

Ethyl 3-[(2*S*)-oxiran-2-ylmethoxy]isonicotinate

To ethyl 3-hydroxyisonicotinate (772 mg, 4.6 mmol) and (2*S*)-oxiran-2-ylmethyl-3-nitrobenzenesulfonate (1.2 g, 4.6 mmol) dissolved in 1-methyl-2-pyrrolidinone (NMP) (9 mL) was added cesium carbonate (1.6 g, 5 mmol). The mixture was stirred under N₂ at ambient temperature 15 h. After extraction from water and ethylacetate, washing, drying and concentrating the organic phase the subtitled product was obtained as a black oil (0.66 g, 64%).

¹H NMR (400 MHz, CDCl₃) δ 8.45 (s, 1H), 8.35 (d, *J* = 4.9 Hz, 1H), 7.61 (d, *J* = 4.9 Hz, 1H), 4.45 (dd, *J* = 2.8 Hz, *J* = 11.0 Hz, 1H), 4.38 (q, *J* = 7.2 Hz, 2H), 4.15 (dd, *J* = 5.3 Hz, *J* = 11.0 Hz, 1H), 3.42 – 3.35 (m, 1H), 2.91 (dd, *J* = 4.1 Hz, 5.0 Hz, 1H), 2.86 (dd, *J* = 2.7 Hz, *J* = 5.0 Hz, 1H), 1.39 (t, *J* = 7.2 Hz, 3H)
APCI-MS: *m/z* 224 [MH⁺]

Step III:

3-{[(2*S*)-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}isonicotinic acid

5-Chloro-3*H*-spiro[1-benzofuran-2,4'-piperidine] (653 mg, 2.9 mmol) and ethyl 3-[(2*S*)-oxiran-2-ylmethoxy]isonicotinate (650 mg, 2.9 mmol) were dissolved in ethanol (6 mL) and stirred at 80°C for 15h. Acetic anhydride (0.3 mL, 3 mmol) was added to trap any unreacted 5-chloro-3*H*-spiro[1-benzofuran-2,4'-piperidine] as amide. The pH was adjusted to 10 by addition of potassium hydroxide solution (2.5 M) and the mixture was stirred for 3 h at ambient temperature. TFA was added till pH≤2 and the solvent removed *in vacuo*. The crude product obtained was purified by preparative HPLC using water and acetonitrile containing 0.1% TFA as mobile phase. The title product was obtained as a yellow amorphous solid (bis(trifluoroacetate) salt, 1.15 g, 61%).

¹H NMR (400 MHz, CD₃OD): δ 8.60 (s, 1H), 8.40 (d, *J* = 5.1 Hz, 1H), 7.85 (d, *J* = 5.1 Hz, 1H), 7.21 (s, 1H), 7.12 (d, *J* = 8.5 Hz, 1H), 6.75 (d, *J* = 8.5 Hz, 1H), 4.54 – 4.45 (m, 1H), 4.41 – 4.34 (m, 1H), 4.33 – 4.26 (m, 1H), 3.82 – 3.63 (m, 1H), 3.58 – 3.37 (m, 4H), 3.14 (s, 2H), 2.31 – 2.14 (m, 4H).

APCI-MS: *m/z* 419 [MH⁺]

Example 24

3-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-*N*-methylisonicotinamide

To a stirred solution of 3-{[(2*S*)-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}isonicotinic acid bis(trifluoroacetate) salt (see Example 23) (38 mg, 91 μmol) and TEA (35 μL, 230 μmol) in THF (4 mL) was added ethyl chloridocarbonate (20 μL, 230 μmol), and the mixture was stirred at ambient temperature for 30 min. Methylamine (2M solution in THF, 125 μL, 230 μmol) was added and the mixture stirred for 1 h. The solvent was evaporated *in vacuo* and the residue dissolved in sodium methoxide solution (1M in methanol, 3 mL) and stirred at ambient temperature for 30 min. Excess of sodium methoxide was neutralized and the crude product was purified

by RP HPLC on silica using acetonitrile and water containing 2 mL 25% ammonia per litre as mobile phase. The title compound was obtained as an amorphous solid (16 mg, 40%).

¹H NMR (300 MHz, acetone-*d*₆) δ 8.58 (s, 1H), 8.45 – 8.30 (br. s, 1H), 8.34 (d, *J* = 4.7 Hz, 1H), 7.83 (d, *J* = 4.9 Hz, 1H), 7.19 – 7.16 (m, 1H), 7.09 (d, *J* = 8.5 Hz, 1H), 6.70 (d, *J* = 8.5 Hz, 1H), 4.57 – 4.47 (m, 1H), 4.33 – 4.20 (m, 2H), 3.05 (s, 2H), 2.91 (d, *J* = 4.7 Hz, 3H), 2.87 – 2.57 (m, 6H), 2.00 – 1.79 (m, 4H)

APCI-MS: *m/z* 432 [MH⁺]

Example 25

(3*S*)-1-(3-([(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy)isonicotinoyl)pyrrolidin-3-ol

A solution of 3-([(2*S*)-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy)isonicotinic acid bis(trifluoroacetate) salt (see Example 23) (65 mg, 0.1 mmol) in THF (3 mL) and 1,1'-carbonylbis-1*H*-imidazole (CDI) (36 mg, 0.22 mmol) was stirred at 70 °C for 30 min. (3*S*)-Pyrrolidin-3-ol (30 mg, 0.33 mmol) was added and the mixture stirred for 2 h at 70°C. The solvent was evaporated *in vacuo* and the residue partitioned between ethylacetate and water (pH≈10). The crude product obtained from the washed organic phase was purified by RP HPLC using acetonitrile and water containing 0.1% TFA as mobile phase. The title product was obtained as a white amorphous solid (31 mg, 40 %).

¹H NMR (400 MHz, CD₃OD): δ 8.66 (s, 0.5H), 8.64 (s, 0.5H), 8.474 (d, *J* = 5.2 Hz, 0.5H), 8.469 (d, *J* = 5.2 Hz, 0.5H), 7.66 (d, *J* = 5.5 Hz, 0.5H), 7.65 (d, *J* = 5.5 Hz, 0.5H), 7.20 (s, 1H), 7.11 (d, *J* = 8.5 Hz, 1H), 6.74 (d, *J* = 8.5 Hz, 1H), 4.57 – 4.52 (m, 0.5H), 4.52 – 4.45 (m, 1H), 4.45 – 4.41 (m, 0.5H), 4.37 – 4.28 (m, 2H), 3.84 – 3.33 (m, 9H), 3.20 (d, *J* = 11.2 Hz, 1H), 3.13 (s, 2H), 2.27 – 1.93 (m, 6H) (mixture of atropisomers, 1 : 1 ratio).

APCI-MS: *m/z* 488 [MH⁺]

THP-1 Chemotaxis Assay

Introduction

- 5 The assay measures the chemotactic response elicited by MIP-1 α chemokine in the human monocytic cell line THP-1. Compounds are evaluated by their ability to depress the chemotactic response to a standard concentration of MIP-1 α chemokine.

Methods

10 **Culture of THP-1 cells**

Cells are thawed rapidly at 37°C from frozen aliquots and resuspended in a 25 cm flask containing 5 ml of RPMI-1640 medium supplemented with Glutamax and 10% heat inactivated fetal calf serum without antibiotics (RPMI+10%HIFCS). At day 3 the medium is discarded and replaced with fresh medium.

15

THP-1 cells are routinely cultured in RPMI-1640 medium supplemented with 10% heat inactivated fetal calf serum and glutamax but without antibiotics. Optimal growth of the cells requires that they are passaged every 3 days and that the minimum subculture density is 4×10^5 cells/ml.

20


Chemotaxis assay

- Cells are removed from the flask and washed by centrifugation in RPMI + 10%HIFCS + glutamax. The cells are then resuspended at 2×10^7 cells/ml in fresh medium (RPMI + 10%HIFCS + glutamax) to which is added calcein-AM (5 μ l of stock solution to 1 ml to
25 give a final concentration of 5×10^{-6} M). After gentle mixing the cells are incubated at 37°C in a CO₂ incubator for 30 minutes. The cells are then diluted to 50 ml with medium and washed twice by centrifugation at 400xg. Labelled cells are then resuspended at a cell concentration of 1×10^7 cells/ml and incubated with an equal volume of MIP-1 α antagonist (10^{-10} M to 10^{-6} M final concentration) for 30 minutes at 37°C in a humidified CO₂
30 incubator.

Chemotaxis is performed using Neuroprobe 96-well chemotaxis plates employing 8 μ m filters (cat no. 101-8). Thirty microlitres of chemoattractant supplemented with various concentrations of antagonists or vehicle are added to the lower wells of the plate in
5 triplicate. The filter is then carefully positioned on top and then 25 μ l of cells preincubated with the corresponding concentration of antagonist or vehicle is added to the surface of the filter. The plate is then incubated for 2 hours at 37°C in a humidified CO₂ incubator. The cells remaining on the surface are then removed by adsorption and the whole plate is centrifuged at 2000 rpm for 10 minutes. The filter is then removed and the cells that have
10 migrated to the lower wells are quantified by the fluorescence of cell associated calcein-AM. Cell migration is then expressed in fluorescence units after subtraction of the reagent blank and values are standardized to % migration by comparing the fluorescence values with that of a known number of labelled cells. The effect of antagonists is calculated as % inhibition when the number of migrated cells is compared with vehicle.

CLAIMS

1. A compound of formula



5 wherein

m is 0, 1, 2, 3 or 4;

each R^1 independently represents halogen, cyano, hydroxyl, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylsulphonyl or sulphonamido;

10 X represents a bond or $-CH_2-$ and Y represents a bond or $-CH_2-$, provided that X and Y do not both simultaneously represent a bond or $-CH_2-$;

n is 0, 1 or 2;

each R^2 independently represents halogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl ;

q is 0 or 1;

15 R^3 represents a saturated or unsaturated 5- to 10-membered ring system other than phenyl, which ring system may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, cyano, oxo, nitro, hydroxyl, carboxyl, $-C(O)H$, $-NR^9R^{10}$, $-C(O)NR^{11}R^{12}$, $-NHC(O)R^{13}$, $-NHSO_2R^{14}$, $-SO_2NR^{15}R^{16}$, $-NHC(O)NR^{17}R^{18}$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, C_1 - C_6 alkylsulphonyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy C_1 - C_6 alkyl, C_1 - C_6 alkylcarbonyl, phenylcarbonyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkylmethyl and a saturated or unsaturated 5- to 6-membered heterocyclic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur;

20 R^4 , R^5 , R^6 , R^7 and R^8 each independently represent hydrogen, halogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl ;

25

R^9 and R^{10} each independently represent hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl;
 R^{11} and R^{12} each independently represent hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl,
or R^{11} and R^{12} together with the nitrogen atom to which they are attached form a 4- to 7-
membered saturated heterocyclic ring which may be optionally substituted with at least one

5 substituent selected from hydroxyl;

R^{13} and R^{14} each independently represent C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl or
 C_1 - C_4 haloalkyl;

R^{15} and R^{16} each independently represent hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl,
or R^{15} and R^{16} together with the nitrogen atom to which they are attached form a 4- to 7-
10 membered saturated heterocyclic ring which may be optionally substituted with at least one
substituent selected from hydroxyl; and

R^{17} and R^{18} each independently represent hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl,
or R^{17} and R^{18} together with the nitrogen atom to which they are attached form a 4- to 7-
membered saturated heterocyclic ring which may be optionally substituted with at least one
15 substituent selected from hydroxyl;

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1, wherein X represents a bond and Y represents
-CH₂-.

20

3. A compound according to claim 1 or claim 2, wherein q is 1.

4. A compound according to any one of claims 1 to 3, wherein m is 1 and R^1 represents
halogen.

25

5. A compound according to any one of claims 1 to 4, wherein R^3 represents an
unsaturated 6- to 10-membered ring system other than phenyl, which ring system may
comprise one or two ring heteroatoms independently selected from nitrogen and oxygen, or
two ring heteroatoms consisting of nitrogen and sulphur, the ring system being optionally
30 substituted with one, two or three substituents independently selected from halogen, oxo,

nitro, -NH₂, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ haloalkyl, C₁-C₄ alkoxyC₁-C₄ alkyl, C₁-C₄ alkylcarbonyl, C₃-C₆ cycloalkylmethyl, -C(O)NR¹¹R¹², carboxyl, and a saturated or unsaturated 5- to 6-membered heterocyclic ring comprising one or two ring heteroatoms independently selected from nitrogen and sulphur.

5

6. A compound according to claim 5, wherein the unsaturated 6- to 10-membered ring system is selected from quinolinyl, 1,2-dihydroquinolinyl, 1,2,3,4-tetrahydroquinolinyl, 2,3-dihydrobenzoxazinyl, 1,2,3,4-tetrahydroquinazolinyl, naphthyl, pyridinyl, benzofuranyl, benzothiazolyl, pyrimidinyl, isoquinolinyl and quinazolinyl.

10

7. A compound according to any one of claims 1 to 6, wherein R⁴, R⁵, R⁶, R⁷ and R⁸ each independently represent hydrogen.

8. A compound according to claim 1 selected from:

15

8-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-3,4-dihydroquinolin-2(1*H*)-one,

8-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}quinolin-2(1*H*)-one,

20

5-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-2*H*-1,4-benzoxazin-3(4*H*)-one,

8-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}quinazoline-2,4(1*H*,3*H*)-dione trifluoroacetate (salt),

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(1-naphthyloxy)propan-2-ol trifluoroacetate (salt),

25

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(6-methyl-2-nitropyridin-3-yl)oxy]propan-2-ol trifluoroacetate (salt),

1-(6-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4,7-dimethoxy-1-benzofuran-5-yl)ethanone trifluoroacetate (salt),

30

(2*S*)-1-[(6-Chloropyridin-2-yl)oxy]-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol trifluoroacetate (salt),

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{[7-(trifluoromethyl)quinolin-4-yl]oxy}propan-2-ol trifluoroacetate (salt),

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-iodo-6-methylpyridin-3-yl)oxy]propan-2-ol trifluoroacetate (salt),

5 (2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{[5-(cyclopropylmethyl)-6-methyl-2-pyridin-4-ylpyrimidin-4-yl]oxy}propan-2-ol trifluoroacetate (salt),

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(quinolin-8-yloxy)propan-2-ol trifluoroacetate (salt),

10 (2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(isoquinolin-5-yloxy)propan-2-ol trifluoroacetate (salt),

(2*S*)-1-[(6-Bromoquinazolin-4-yl)oxy]-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol trifluoroacetate (salt),

15 (2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{[2-(2-thienyl)-6-(trifluoromethyl)pyrimidin-4-yl]oxy}propan-2-ol trifluoroacetate (salt),

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(quinolin-5-yloxy)propan-2-ol trifluoroacetate (salt),

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2,3,4-trichloro-1-naphthyl)oxy]propan-2-ol trifluoroacetate (salt),

20 (2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{[1-(1,3-dithiolan-2-yl)-2-naphthyl]oxy}propan-2-ol trifluoroacetate (salt),

(2*S*)-1-{[5-Butyl-6-(methoxymethyl)-2-(methylthio)pyrimidin-4-yl]oxy}-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol trifluoroacetate (salt),

25 (2*S*)-1-[(2-Amino-1,3-benzothiazol-4-yl)oxy]-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,

(2*S*)-1-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-methyl-1,3-benzothiazol-4-yl)oxy]propan-2-ol,

(2*S*)-1-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-methyl-1-benzofuran-4-yl)oxy]propan-2-ol,


3-{[(2*S*)-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}isonicotinic acid,

3-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-*N*-methylisonicotinamide,


- 5 (3*S*)-1-(3-{[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}isonicotinoyl)pyrrolidin-3-ol,
and pharmaceutically acceptable salts and solvates of any one thereof.

9. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in claim 1 which comprises,

(a) reacting a compound of formula




wherein m , R^1 , n , R^2 , q , X and Y are as defined in formula (I), with a compound of formula



15


wherein R^3 , R^4 , R^5 , R^6 , R^7 and R^8 are as defined in formula (I); or

(b) reacting a compound of formula



46


wherein m , R^1 , n , R^2 , q , X , Y , R^4 , R^5 , R^6 , R^7 and R^8 are as defined in formula (I), with a compound of formula



wherein R^3 is as defined in formula (I), in the presence of a suitable base;

5


(c) when R^3 is substituted with $-C(O)NR^{11}R^{12}$, reacting a compound of formula



10

wherein L represents a leaving group (e.g. a hydroxyl group), $R^{3'}$ is a saturated or unsaturated 5- to 10-membered ring system other than phenyl, which ring system may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, and m , R^1 , n , R^2 , q , X , Y , Z , R^4 , R^5 , R^6 , R^7 and R^8 are as defined in formula (I), with a compound

15 of formula (VII),



20

wherein R^{11} and R^{12} are as defined in formula (I), in the presence of a suitable coupling reagent;

and optionally after (a), (b) or (c) forming a pharmaceutically acceptable salt or solvate.

10. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 5 11. A process for the preparation of a pharmaceutical composition as claimed in claim 10 which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 10 12. A compound of formula (I) or a pharmaceutically-acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 for use in therapy.
13. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for the
15 treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.
14. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use
20 in treating rheumatoid arthritis.
15. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating chronic obstructive pulmonary disease.
25
16. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating asthma.

17. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating multiple sclerosis.

5 18. A method of treating an inflammatory disease which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8.

10 19. A method of treating an airways disease which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/001771

A. CLASSIFICATION OF SUBJECT MATTER

C07D491/10, 471/10, 221/20, 209/54, A61K31/438, 31/403, 31/407,

IPC7: A61P 11/06, 11/08, 19/02, 29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9825605 A1 (MERCK & CO., INC.), 18 June 1998 (18.06.1998), see particularly examples 30-42 --	1-19
A	WO 0014086 A1 (LEUKOSITE, INC.), 16 March 2000 (16.03.2000), see particularly examples 68-77 --	1-19
A	Eur J Med Chem, Vol. 31, 1996, MD Pujol et al: "Novel tricyclic spiropiperidines. Synthesis and adrenergic activity of spiro(1,3-benzodioxolopiperidines) and spiro(1,3-benzodioxanepiperidines)", page 889 - page 894 --	1-19

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

4 March 2005

Date of mailing of the international search report

09-03-2005

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Eva Johansson/EÖ

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/001771

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 0164213 A1 (SMITHKLINE BEECHAM CORPORATION), 7 Sept 2001 (07.09.2001) --	1-19
A	WO 9831364 A1 (MERCK & CO., INC.), 23 July 1998 (23.07.1998) --	1-19
A	EP 0004951 A1 (HOECHST AKTIENGESELLSCHAFT), 31 October 1979 (31.10.1979) --	1-19
A	WO 02102387 A1 (H. LUNDBECK A/S), 27 December 2002 (27.12.2002) --	1-19
P,A	WO 2004005295 A1 (ASTRAZENECA AB), 15 January 2004 (15.01.2004) -- -----	1-19

INTERNATIONAL SEARCH REPORT

I application No.
SE2004/001771

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18, 19
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 18-19 relate to a method of treatment of the human or animal body by surgery or by therapy, as well as diagnostic
.../...
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Int al application No.
SE2004/001771

Box II.1

methods /Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/001771

WO	9825605	A1	18/06/1998	AU	737107 B	09/08/2001
				AU	4954297 A	29/05/1998
				AU	5803398 A	03/07/1998
				CA	2271146 A	14/05/1998
				EP	0937244 A	25/08/1999
				GB	9703005 D	00/00/0000
				NZ	335885 A	26/01/2001
				US	6387232 B	14/05/2002
				US	5962462 A	05/10/1999

WO	0014086	A1	16/03/2000	AU	2464999 A	27/03/2000
				CA	2342882 A	16/03/2000
				EP	1109804 A	27/06/2001
				JP	2002524458 T	06/08/2002
				US	6288083 B	11/09/2001
				US	6288084 B	11/09/2001
				US	6503926 B	07/01/2003
				US	20020161005 A	31/10/2002

WO	0164213	A1	07/09/2001	AU	4339401 A	12/09/2001

WO	9831364	A1	23/07/1998	AU	6133098 A	07/08/1998
				CA	2278309 A	23/07/1998
				EP	1003743 A	31/05/2000
				GB	9707490 D	00/00/0000
				JP	2001508798 T	03/07/2001
				US	6124319 A	26/09/2000

EP	0004951	A1	31/10/1979	CA	1132988 A	05/10/1982
				CA	1132989 A	05/10/1982
				DE	2961804 D	00/00/0000
				ES	479368 A	16/07/1979
				JP	54145660 A	14/11/1979
				US	4166120 A	28/08/1979

WO	02102387	A1	27/12/2002	NONE		

WO	2004005295	A1	15/01/2004	AU	2002353713 A	00/00/0000
				CA	2462819 A	30/05/2003
				EP	1451356 A	01/09/2004
				SE	0202133 D	00/00/0000
				US	20050003361 A	06/01/2005
